Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medication discontinuation in panic disorder

J C Ballenger1, J Pecknold, K Rickels

  • 1Institute of Psychiatry, Medical University of South Carolina, Charleston 29425.

The Journal of Clinical Psychiatry
|October 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psilocybin: Good Trip or Bad Trip.

Clinical pharmacology and therapeutics·2017
Same author

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.

The Journal of pharmacology and experimental therapeutics·2016
Same author

Deconstructing Designer Drugs.

Clinical pharmacology and therapeutics·2016
Same author

The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Clinical pharmacology and therapeutics·2016
Same author

From the benches to the trenches : training residents to provide emergency outreach services-a public/academic project.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2014
Same author

Update on tamper-resistant drug formulations.

Drug and alcohol dependence·2013
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Most patients can stop benzodiazepines with slow tapering, especially after short-term use. Long-term, high-dose users may face challenges, but symptoms are usually mild and temporary if managed properly.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Psychology

Background:

  • Panic disorder is frequently treated with benzodiazepines.
  • Medication discontinuation presents unique challenges for patients.
  • Benzodiazepine discontinuation requires careful management strategies.

Purpose of the Study:

  • To review current issues in panic disorder medication discontinuation.
  • To focus on benzodiazepine discontinuation challenges and management.
  • To provide guidance for safe and effective benzodiazepine cessation.

Main Methods:

  • Literature review of benzodiazepine discontinuation in panic disorder.
  • Analysis of factors influencing discontinuation difficulty (therapy duration, dosage).
  • Examination of management strategies for discontinuation symptoms and relapse.

Related Experiment Videos

Main Results:

  • Majority of patients achieve successful benzodiazepine discontinuation with slow tapering.
  • Short-term therapy patients generally experience easier discontinuation.
  • Long-term, high-dose therapy may lead to increased discontinuation difficulty.
  • Discontinuation symptoms, if present, are typically transient and manageable with proper preparation and gradual tapering.
  • Relapse of panic disorder during discontinuation complicates management.

Conclusions:

  • Gradual tapering and patient preparation are key to successful benzodiazepine discontinuation.
  • While discontinuation symptoms can occur, they are usually manageable.
  • Preventing relapse during the discontinuation process is crucial for effective clinical management.